MA51899A - Inhibiteurs de btk et de leurs mutants - Google Patents
Inhibiteurs de btk et de leurs mutantsInfo
- Publication number
- MA51899A MA51899A MA051899A MA51899A MA51899A MA 51899 A MA51899 A MA 51899A MA 051899 A MA051899 A MA 051899A MA 51899 A MA51899 A MA 51899A MA 51899 A MA51899 A MA 51899A
- Authority
- MA
- Morocco
- Prior art keywords
- btk
- mutants
- inhibitors
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q20/00—Payment architectures, schemes or protocols
- G06Q20/30—Payment architectures, schemes or protocols characterised by the use of specific devices or networks
- G06Q20/34—Payment architectures, schemes or protocols characterised by the use of specific devices or networks using cards, e.g. integrated circuit [IC] cards or magnetic cards
- G06Q20/349—Rechargeable cards
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K19/00—Record carriers for use with machines and with at least a part designed to carry digital markings
- G06K19/06—Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
- G06K19/067—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components
- G06K19/07—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips
- G06K19/0723—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips the record carrier comprising an arrangement for non-contact communication, e.g. wireless communication circuits on transponder cards, non-contact smart cards or RFIDs
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q20/00—Payment architectures, schemes or protocols
- G06Q20/30—Payment architectures, schemes or protocols characterised by the use of specific devices or networks
- G06Q20/34—Payment architectures, schemes or protocols characterised by the use of specific devices or networks using cards, e.g. integrated circuit [IC] cards or magnetic cards
- G06Q20/341—Active cards, i.e. cards including their own processing means, e.g. including an IC or chip
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Business, Economics & Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Theoretical Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Business, Economics & Management (AREA)
- Strategic Management (AREA)
- Accounting & Taxation (AREA)
- Computer Hardware Design (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862631945P | 2018-02-19 | 2018-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51899A true MA51899A (fr) | 2020-12-30 |
Family
ID=65685969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051899A MA51899A (fr) | 2018-02-19 | 2019-02-15 | Inhibiteurs de btk et de leurs mutants |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11501284B2 (fr) |
| EP (1) | EP3755702A1 (fr) |
| JP (1) | JP7535949B2 (fr) |
| KR (1) | KR102861971B1 (fr) |
| CN (2) | CN117209502A (fr) |
| AU (1) | AU2019222475B2 (fr) |
| CA (1) | CA3088796A1 (fr) |
| IL (1) | IL276575B2 (fr) |
| MA (1) | MA51899A (fr) |
| MX (1) | MX2020008627A (fr) |
| SG (1) | SG11202006274XA (fr) |
| WO (1) | WO2019161152A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102861971B1 (ko) * | 2018-02-19 | 2025-09-19 | 광조우 루펭 파마슈티칼 컴퍼니 엘티디. | Btk 및 그의 돌연변이체의 억제제 |
| WO2020176403A1 (fr) * | 2019-02-25 | 2020-09-03 | Newave Pharmaceutical Inc. | Inhibiteurs de btk et leurs mutants |
| WO2021038540A1 (fr) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Acides cycloalkylidènecarboxyliques et dérivés en tant qu'inhibiteurs de la btk |
| US20220363689A1 (en) * | 2019-10-05 | 2022-11-17 | Newave Pharmaceutical Inc. | Inhibitor of btk and mutants thereof |
| IL295589A (en) | 2020-02-20 | 2022-10-01 | Hutchison Medipharma Ltd | The heterocyclic heteroaryl compounds and their uses |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| AU2021326530A1 (en) * | 2020-08-14 | 2023-04-20 | Guangzhou Lupeng Pharmaceutical Company Ltd. | Dosage form compositions comprising an inhibitor of btk and mutants thereof |
| CN121226379A (zh) | 2020-09-21 | 2025-12-30 | 和记黄埔医药(上海)有限公司 | 杂芳基杂环化合物及其用途 |
| CN117897388A (zh) * | 2020-12-20 | 2024-04-16 | 广州麓鹏制药有限公司 | Btk蛋白降解剂 |
| US20240058457A1 (en) * | 2020-12-20 | 2024-02-22 | Newave Pharmaceutical Inc. | Btk degrader |
| CN115960124B (zh) * | 2023-02-23 | 2025-02-18 | 康化(上海)新药研发有限公司 | 一种2-氟-3-甲酰基-吡啶-4-硼酸频哪醇酯的合成方法 |
| WO2025031344A1 (fr) | 2023-08-07 | 2025-02-13 | 广州麓鹏制药有限公司 | Forme cristalline vi d'un composé d'acrylamide, son procédé de préparation et son utilisation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| SG10202107066WA (en) | 2007-03-28 | 2021-07-29 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| NZ603525A (en) | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| EP2566869B1 (fr) * | 2010-05-07 | 2016-03-02 | Gilead Connecticut, Inc. | Composés de pyridone et d'aza-pyridone et leurs procédés d'utilisation |
| UA111756C2 (uk) * | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| EP2964642B1 (fr) | 2013-03-05 | 2017-11-15 | F. Hoffmann-La Roche AG | Inhibiteurs de la tyrosine kinase de bruton |
| WO2014210255A1 (fr) | 2013-06-26 | 2014-12-31 | Abbvie Inc. | Carboxamides primaires servant d'inhibiteurs de la btk |
| WO2015050703A1 (fr) * | 2013-10-04 | 2015-04-09 | Yi Chen | Inhibiteurs de la tyrosine kinase de bruton |
| WO2015082583A1 (fr) * | 2013-12-05 | 2015-06-11 | F. Hoffmann-La Roche Ag | Composés de pyridone hétéroarylique et d'aza-pyridone à fonctionnalité électrophile |
| WO2018109050A1 (fr) | 2016-12-15 | 2018-06-21 | F. Hoffmann-La Roche Ag | Procédé de préparation d'inhibiteurs de btk |
| EP3746426A4 (fr) | 2018-01-29 | 2021-12-29 | Dana Farber Cancer Institute, Inc. | Dégradation de tyrosine kinase de bruton (btk) par conjugaison d'inhibiteurs de btk avec un ligand de ligase e3 et procédés d'utilisation |
| KR102861971B1 (ko) * | 2018-02-19 | 2025-09-19 | 광조우 루펭 파마슈티칼 컴퍼니 엘티디. | Btk 및 그의 돌연변이체의 억제제 |
| WO2020176403A1 (fr) | 2019-02-25 | 2020-09-03 | Newave Pharmaceutical Inc. | Inhibiteurs de btk et leurs mutants |
| US20220363689A1 (en) | 2019-10-05 | 2022-11-17 | Newave Pharmaceutical Inc. | Inhibitor of btk and mutants thereof |
| US20230024442A1 (en) | 2019-11-08 | 2023-01-26 | Nurix Therapeutics, Inc. | Bifunctional compounds for grading btk via ubiquitin proteosome pathway |
-
2019
- 2019-02-15 KR KR1020207026689A patent/KR102861971B1/ko active Active
- 2019-02-15 CN CN202311008387.0A patent/CN117209502A/zh active Pending
- 2019-02-15 CN CN201980013997.5A patent/CN111741959B/zh active Active
- 2019-02-15 AU AU2019222475A patent/AU2019222475B2/en active Active
- 2019-02-15 IL IL276575A patent/IL276575B2/en unknown
- 2019-02-15 MX MX2020008627A patent/MX2020008627A/es unknown
- 2019-02-15 WO PCT/US2019/018139 patent/WO2019161152A1/fr not_active Ceased
- 2019-02-15 EP EP19709178.8A patent/EP3755702A1/fr active Pending
- 2019-02-15 CA CA3088796A patent/CA3088796A1/fr active Pending
- 2019-02-15 SG SG11202006274XA patent/SG11202006274XA/en unknown
- 2019-02-15 MA MA051899A patent/MA51899A/fr unknown
- 2019-02-15 JP JP2020566200A patent/JP7535949B2/ja active Active
-
2020
- 2020-08-18 US US16/996,516 patent/US11501284B2/en active Active
-
2022
- 2022-10-10 US US17/962,798 patent/US12086788B2/en active Active
-
2024
- 2024-08-08 US US18/798,308 patent/US20250045728A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111741959A (zh) | 2020-10-02 |
| JP7535949B2 (ja) | 2024-08-19 |
| WO2019161152A1 (fr) | 2019-08-22 |
| CN117209502A (zh) | 2023-12-12 |
| US20200377478A1 (en) | 2020-12-03 |
| EP3755702A1 (fr) | 2020-12-30 |
| AU2019222475B2 (en) | 2024-08-15 |
| IL276575B1 (en) | 2024-01-01 |
| CN111741959B (zh) | 2023-09-05 |
| CA3088796A1 (fr) | 2019-08-22 |
| IL276575B2 (en) | 2024-05-01 |
| US20250045728A1 (en) | 2025-02-06 |
| US20230140433A1 (en) | 2023-05-04 |
| US11501284B2 (en) | 2022-11-15 |
| MX2020008627A (es) | 2020-09-21 |
| JP2021514390A (ja) | 2021-06-10 |
| US12086788B2 (en) | 2024-09-10 |
| AU2019222475A1 (en) | 2020-07-30 |
| KR102861971B1 (ko) | 2025-09-19 |
| SG11202006274XA (en) | 2020-07-29 |
| IL276575A (en) | 2020-09-30 |
| KR20200122348A (ko) | 2020-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51899A (fr) | Inhibiteurs de btk et de leurs mutants | |
| EP3870579A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| IL283592A (en) | Inhibitors of apol1 and methods of using same | |
| IL287223A (en) | Kras g12c inhibitors and methods of using the same | |
| EP3866789A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| IL287940A (en) | Fgfr inhibitors and methods of use thereof | |
| EP3886843A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| IL271025A (en) | Multibiotic agents and methods of using the same | |
| EP3768664A4 (fr) | Inhibiteurs de shp2 et leurs utilisations | |
| DK3774789T3 (da) | BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse | |
| DK3788044T3 (da) | RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf | |
| EP3700527A4 (fr) | Inhibiteurs de papd5 et leurs méthodes d'utilisation | |
| DK3737765T4 (da) | Forstærkede immunceller med dobbelt shrna og sammensætning dermed | |
| EP3746075A4 (fr) | Inhibiteurs de gcn2 et leurs utilisations | |
| IL287768A (en) | Kcnt1 inhibitors and methods of use | |
| IL287751A (en) | Kcnt1 inhibitors and methods of use | |
| IL283106A (en) | Erk inhibitors and uses thereof | |
| IL281438A (en) | Pyridazinones and methods of use thereof | |
| EP3938369A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| DK3710430T3 (da) | Acss2-inhibitorer og fremgangsmåder til anvendelse deraf | |
| EP3801500A4 (fr) | Inhibiteurs de sarm1 | |
| HRP20251592T1 (hr) | Inhibitori arginaze i metode njihove primjene | |
| HUE052468T2 (hu) | Arginázgátlók és terápiás alkalmazásaik | |
| IL283782A (en) | Anellosomes and methods of use | |
| EP3914357A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations |